
Gary Steinberg
Chair, Stanford University School of Medicine - Neurosurgery · Stanford Health Care
Credentials: · · · ·
History
- Present
Stanford University School of Medicine - Neurosurgery Department · Stanford Health Care
- Present
Stanford Moyamoya Center · Stanford Health Care
- Present
Stanford Stroke Center · Stanford Health Care
- 1986–1987
Stanford University Dept of Neurosurgery (1987) CA
- 1983–1986
1981–1983Stanford University Dept of General Surgery (1983) CA
- 1980–1981
Institute Of Neurology (1981) England
- 1978–1981
Institute Of Neurology (1981) England

Research
Neuron · 2016 · 1,813 citations
Proceedings of the National Academy of Sciences of the United States of America · 2012 · 1,402 citations
Neuron · 2014 · 555 citations

81 papers
- MY
43 papers · 4 as a fellow

41 papers

40 papers · 1 as a fellow
- RG
25 papers

24 papers · 1 as a fellow

20 papers · 6 as a fellow

17 papers
Grants
- 2015–2026
Optogenetic Approaches to Study Post-Stroke Recovery Mechanisms
National Institute of Neurological Disorders and Stroke · R01
Contact PI · $5.8M · Stanford University
- 2008–2026
Multimodal Approach Investigating the Immunomodulatory Effect Ofneural Stem Cells in Stroke Recovery
National Institute of Neurological Disorders and Stroke · R01
Contact PI · $6.6M · Stanford University
- 2021–2023
National Institute of Neurological Disorders and Stroke · R21
Contact PI · $432.9K · Stanford University
- 2009–2022
Stanford Neurosurgery and Neurology Resident Research Education Program
National Institute of Neurological Disorders and Stroke · R25
PI · $1.9M · Stanford University
Clinical trials
- 2016–2018
Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke
Principal investigator · Completed · Phase 2
SanBio, Inc.
- 2011–2015
A Study of Modified Stem Cells in Stable Ischemic Stroke
Principal investigator · Completed · Phase 1, Phase 2
SanBio, Inc.
- 2027–2029
CC-101 (f/k/a NR1) Neural Stem Cell Transplantation for Adults With Chronic Ischemic Stroke
Study chair · Not yet recruiting · Phase 2
Clarion Cells, Inc.


